Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (Becton, Dickinson and Company) released survey results showing a significant knowledge gap among U.S. women about cervical cancer causes and prevention. Conducted by Harris Poll, 71% of women reported delaying Pap tests, with minority groups disproportionately affected. Despite 91% claiming general health knowledge, many lack understanding of cervical cancer screenings, with 67% unaware that HPV causes most cervical cancers. The survey indicates a need for improved education and access to self-collection kits as 79% of women show interest in them.
BD (Becton, Dickinson and Company) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 pm Eastern Time. The live webcast will be available on the BD investor relations website, with a replay accessible post-event. BD is a global leader in medical technology, committed to advancing health care through innovative solutions and technology, showcasing its presence in numerous countries and focus on improving care delivery.
BD (Becton, Dickinson and Company) (NYSE: BDX) will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 8:00 am Eastern Time. The presentation will be accessible via BD's investor relations website, with a replay available post-event.
BD is a leading global medical technology firm focused on enhancing health through innovative technologies and solutions. With a workforce of 77,000, BD partners globally to tackle health challenges and improve care delivery.
BD (Becton, Dickinson and Company) reported Q4 revenue of $4.8 billion, down 1.8% year-over-year, but up 2.3% on a currency-neutral basis. For FY22, revenue was $18.9 billion, also decreasing by 1.4%. Q4 GAAP diluted EPS rose 100% to $0.92, while adjusted EPS increased 27.9% to $2.75. The company maintains a robust outlook, projecting FY23 revenue between $18.6 billion and $18.8 billion with adjusted diluted EPS expected to be $11.85 to $12.10. BD also marked its 51st consecutive year of dividend increases, raising it by 4.6%. The company continues to execute on its BD 2025 strategy.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per share, marking a 4.6% increase from the prior quarter. This dividend will be paid on Dec. 30, 2022, to those on record by Dec. 9, 2022. For the fiscal year 2023, the projected annual dividend rate is $3.64 per share. This represents the 51st consecutive year of dividend increases, reaffirming BD’s status as a component of the S&P 500 Dividend Aristocrats Index.
BD (Becton, Dickinson and Company) (NYSE: BDX) has entered a co-exclusive commercial agreement with Magnolia Medical Technologies to reduce blood culture contamination in U.S. hospitals. The collaboration will promote Magnolia Medical's Steripath® Initial Specimen Diversion Device®, which is FDA-cleared to enhance testing accuracy for sepsis. This device meets the new 1% blood culture contamination guideline set by the CDC. Clinical studies support its effectiveness, with many hospitals adopting it to improve patient outcomes and reduce healthcare costs associated with contamination.
BD (NYSE: BDX) has entered into a collaboration with Biocorp to enhance self-administered drug therapies through connected technology. The partnership aims to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Passive Needle Guard, allowing biopharmaceutical manufacturers to capture and transmit injection data. This innovation is expected to improve patient adherence to injectable drugs. The connected drug delivery market is projected to grow significantly as digital technologies and self-administered therapies become more prevalent.
BD (Becton, Dickinson and Company) will announce its fiscal 2022 fourth quarter and full year financial results on November 10, 2022, at approximately 6:30 a.m. ET. The announcement will provide summarized financial information for the quarter and full year ending on September 30, 2022.
An audio webcast will follow at 8 a.m. ET on the same day to discuss the results and company operations. Investors can access the release and the webcast on BD's investor relations website.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
